Page 29 - 《中国药房》网络版（科普刊）2024年6期

2024 年 12 月 第 6 期 Xia Ye：Searching for the Trojan Horse Humanistic Pharmacy： From Dream to Reality in 25 Years 25

chemotherapy. In 1994， Sanofi acquired oxaliplatin from Debiopharm and obtained the rights for
further development. Oxaliplatin， under the brand name Eloxatin， was first marketed in France in

1996. It received FDA approval in the U. S. in 2002 and won the prestigious French Prix Galien

Award in 2004. Interestingly， Eloxatin was approved in China three years earlier， in 1998.

As a pharmacist， I understand the complexity and challenges behind these developments. My

own cancer treatment primarily involved the FOLFOX regimen， which includes both targeted therapy

and chemotherapy. Despite the severe side effects， I remain deeply grateful to the scientists who
dedicated their courage and humanistic spirit to new drug development. Sometimes， they seize

fleeting opportunities； other times， they endure long waits； and sometimes， they can only leave the

results to luck.

The years pass like a song. Nearly 180 years have passed since 1845， 60 years since 1963， and

exactly 30 years since 1994. Throughout these years， humanity has relentlessly pursued the
anticancer potential of platinum. In moments of ambiguity， frustration， failure， and hope for the

future， scientists have never given up on researching this valuable class of drugs. What exactly they